Prevalence of atrophic gastritis in dyspeptic patients in Piedmont. A survey using the GastroPanel test

Lombardo, L; Leto, Rosalia; Molinaro, G.C.; Migliardi, Marco; Ravarino, Nicoletta; Rocca, Rodolfo; Torchio, Bruno

doi:10.1515/cclm.2010.256

Cited by 17 publications

(21 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…PGI levels are significantly lower in patients with corpus fundus atrophic gastritis than in controls without atrophic gastritis, and G17 levels are significantly lower in antral atrophic gastritis than in normal controls. The agreement between GastroPanel and histology for corpus-prevalent chronic atrophic gastritis was 94%, results which encourage us to use GastroPanel as a reliable non-invasive test for diagnosis of chronic atrophic gastritis [10].…”

Section: Gastro Panel a Reliable Non-invasive Testmentioning

confidence: 74%

“…Another study based on 162 subjects from Tohoku University from 2006 to 2008 obtained a very good accuracy, sensitivity and specificity, 94%, 95% and 93% respectively for GastroPanel test in diagnosing healthy stomach mucosa [10]. In countries with a high incidence of gastric cancer, such as Japan and Korea, the Cancer Control Program started in 2012 was conducted in conjunction with H. pylori eradication and also accepted the measurement of serum PG as a noninvasive screening test of gastric cancer to identify individuals at high risk [11].…”

Section: Gastro Panel a Reliable Non-invasive Testmentioning

confidence: 97%

See 1 more Smart Citation

Helicobacter pylori Infection, Gastric Cancer and Gastropanel

Loor

Dumitraşcu

2016

Romanian Journal of Internal Medicine

View full text Add to dashboard Cite

Gastric cancer (GC) is one of the most widespread types of cancer worldwide. Helicobacter pylori infection has been clearly correlated with gastric carcinogenesis. At present and in the near future, the most important challenge is and will be the significant reduction of mortality due to GC. That goal can be achieved through the identification of higher-risk patients, such as those with atrophic gastritis, intestinal metaplasia and dysplasia. In this review we intend to discuss the importance of diagnosing H. pylori infection and chronic atrophic gastritis in preventing gastric cancer, using a new non-invasive test called GastroPanel. This test is a classification algorithm including four biochemical parameters pepsinogen I and II (PGI and PGII), gastrin-17 (G17), and anti-Helicobacter pylori antibodies (Ig G anti-Hp) measured in fasting sera, which allows to classify patients as having atrophic or non-atrophic gastritis and to find whether gastritis is associated or not with H. pylori infection. GastroPanel is not a "cancer test", but it can and should be used in the screening and diagnosis of subjects with a high cancer risk; still, a careful diagnostic made by superior digestive endoscopy is compulsory to find possible precancerous or cancerous lesions at an early and curable stage.

show abstract

Section: Gastro Panel a Reliable Non-invasive Testmentioning

confidence: 74%

Section: Gastro Panel a Reliable Non-invasive Testmentioning

confidence: 97%

Helicobacter pylori Infection, Gastric Cancer and Gastropanel

Loor

Dumitraşcu

2016

Romanian Journal of Internal Medicine

View full text Add to dashboard Cite

show abstract

“…Serum samples of 1387 patients from northern Italy who initially presented with dyspeptic symptoms have been collected, and gastroscopy was performed on 400 consecutive patients with biopsy sampling from the antrum and the corpus [40]. Agreement between low pepsinogen I testing and the histological analysis was 94% for corpus prevalent chronic atrophic gastritis (sensitivity 80% and specifity 96%).…”

Section: H Pylori As High Risk Indicatormentioning

confidence: 99%

Gastric Cancer: Clinical Aspects, Epidemiology and Molecular Background

et al. 2011

View full text Add to dashboard Cite

In 2010, the WHO introduced the seventh edition of the tumor node metastasis (TNM) classification that provides a more detailed classification for both local tumor invasion (T) and lymph node involvement (N) compared with the previous version. The T and N categories of tumors located in the stomach have been further modified with the intention to ensure a better correlation to the prognostic outcome. For the classification of a pN0, the number of lymph nodes has been adjusted to 16.The description of tumors with origin in the esophagus has been simplified and includes tumors of the esophagogastric junction as well as gastric tumors extending to the proximal 5 cm of the stomach. Major changes are further the subclassification of the categories T1 and T4 and the new N categorization now considering the number of lymph nodes involved within tree categories. Furthermore, positive lymph nodes in the region of the celiac trunc are considered as regional in case of esophageal cancers.The validity of the new classification system in its prognostic efficacy was compared to the previous edition. A study conducted in China proved a better prognostic stratification for the new actualized version [1]. Another study from Korea showed similar results for the new TNM system, proving a more detailed prognostic assessment, especially between T2 and T3 and N1 and N2 tumors [2]. The advantage of the new (7th) edition was mainly confirmed for the prognostic value of accurate lymph node assessment [3].Concerning the classification of early gastric cancer (GC) in the new system, a study from Italy confirmed the usefulness of the new classification for metastatic lymph nodes as a prognostic tool in case of early GC. AbstractThe validity and usefulness of the 7th edition of the UICC tumor node metastasis classification in the context of clinical management of gastric cancer are discussed. The most relevant new agent in gastric cancer therapy is trastuzumab for HER2-positive gastric carcinomas. This marks the success of continuous effort of translational research. Trastuzumab, initially applied in palliative settings, is currently being evaluated also in neoadjuvant treatment regimens. Several new meta-analyses support the carcinogenic effect of high salt intake and smoking in the context of Helicobacter pylori infection. Further data have become available on the efficacy of protective agents, acetyl salicylic acid ⁄ nonsteroidal anti-inflammatory drugs, and antioxidants. In search for a successful prevention strategy, the focus is on the identification of individuals at high risk who demand screening (testing) and surveillance. Serological assessment of gastric mucosal abnormalities with increased risk for gastric cancer development is extensively studied, and new data are presented from Asia as well as from Europe. New high-throughput techniques combined with bioinformatic vector analysis open the gate to the identification of new potential diagnostic and therapeutic targets. Furthermore, these approaches allow us to elucidate the int...

show abstract

“…The results on GP's sensitivity (SE) and specificity (SP) in diagnosis of AG have been variable (10)(11)(12)(13)(23)(24)(25)(26)(27)(28)(29)(30)(31)(32)(33)(34). There are several potential sources of bias affecting GP performance in different settings (22,25).…”

mentioning

confidence: 99%